Subject(s)
Bacterial Infections/transmission , Breast Feeding , Infant Food , Puerperal Infection/transmission , Adult , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Bacterial Infections/metabolism , Endometritis/drug therapy , Endometritis/metabolism , Female , Humans , Infant, Newborn , Mastitis/drug therapy , Mastitis/metabolism , Milk, Human/drug effects , Puerperal Infection/drug therapy , Puerperal Infection/metabolismSubject(s)
Diagnosis, Computer-Assisted/trends , Mastitis/diagnosis , Puerperal Disorders/diagnosis , Female , Humans , Minicomputers , Pregnancy , PrognosisSubject(s)
Bacterial Infections/drug therapy , Endometritis/drug therapy , Puerperal Infection/drug therapy , Anti-Bacterial Agents/administration & dosage , Bacterial Infections/etiology , Drug Therapy, Combination , Endometritis/etiology , Female , Humans , Metronidazole/administration & dosage , Pregnancy , Puerperal Infection/etiologyABSTRACT
The study revealed the dominating role of aerobic-anaerobic microbial associations and in particular the specific role of anaerobic gram positive cocci in development of puerperal endometritis. The data suggested that a definite level of the uterus cavity contamination with microbes, not lower than 10(4)-10(5) CFU/ml or a large number of bacterial associates, not less than 3 was necessary for endometritis development. It was confirmed that pathogenicity of anaerobes increased in the presence of aerobic bacteria. It is concluded that quantitative methods for detecting the main causative agents of endometritis are needed. A set of antibacterial drugs for rational antibacterial therapy of puerperal endometritis is recommended.
Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteria, Aerobic/drug effects , Bacteria, Anaerobic/drug effects , Bacterial Infections/etiology , Endometritis/etiology , Puerperal Infection/etiology , Bacteria, Aerobic/isolation & purification , Bacteria, Anaerobic/isolation & purification , Bacterial Infections/microbiology , Endometritis/microbiology , Female , Humans , Microbial Sensitivity Tests , Pregnancy , Puerperal Infection/microbiology , Uterus/microbiologySubject(s)
Immunologic Deficiency Syndromes/etiology , Puerperal Infection/complications , Adult , Female , Humans , PregnancySubject(s)
Bacterial Infections/etiology , Endometritis/etiology , Puerperal Infection/etiology , Bacteria, Aerobic/isolation & purification , Bacteria, Anaerobic/isolation & purification , Bacterial Infections/microbiology , Endometritis/microbiology , Female , Humans , Pregnancy , Puerperal Infection/microbiology , Uterus/microbiologySubject(s)
Ampicillin/metabolism , Cefuroxime/metabolism , Cephalosporins/metabolism , Endometritis/drug therapy , Kanamycin/metabolism , Puerperal Infection/drug therapy , Adult , Ampicillin/therapeutic use , Cefuroxime/therapeutic use , Female , Humans , Kanamycin/therapeutic use , Kinetics , Milk, Human/metabolism , PregnancySubject(s)
Bacterial Infections/etiology , Puerperal Infection/etiology , Pyelonephritis/etiology , Bacterial Infections/diagnosis , Bacterial Infections/drug therapy , Female , Humans , Pregnancy , Puerperal Infection/diagnosis , Puerperal Infection/drug therapy , Pyelonephritis/diagnosis , Pyelonephritis/drug therapySubject(s)
Bromocriptine/therapeutic use , Mastitis/drug therapy , Puerperal Disorders/drug therapy , Female , Humans , PregnancyABSTRACT
The use of cephotaxim in the treatment of obstetric and gynecological patients with various infectious complications, as well as in the treatment of newborn infants in the Department of Intensive Therapy showed it to be highly effective in 100 per cent of the cases. The adverse reactions of cephotaxim were observed in 1 out of 43 patients. It should be noted that cephotaxim did not inhibit the host anaerobic indigenous flora. No cases of dysbacteriosis were recorded. Comparative analysis of the data on determination of the MIC of cephotaxim and cephuroxim with respect to various species of opportunistic microorganisms demonstrated that cephuroxim was more active against Staph. aureus, while cephotaxim against Klebsiella. Cephotaxim displayed activity against part of the strains of Ps. aeruginosa and streptococci of group D, which was not common to cephalosporins of the previous generations.
Subject(s)
Bacterial Infections/drug therapy , Cefotaxime/therapeutic use , Cefuroxime/therapeutic use , Cephalosporins/therapeutic use , Infant, Newborn, Diseases/drug therapy , Puerperal Infection/drug therapy , Cefuroxime/metabolism , Cephalosporins/metabolism , Endometritis/drug therapy , Enterococcus faecalis/drug effects , Escherichia coli/drug effects , Female , Humans , Infant, Newborn , Kinetics , Klebsiella/drug effects , Pregnancy , Pseudomonas aeruginosa/drug effects , Pyelonephritis/drug therapy , Staphylococcus aureus/drug effectsABSTRACT
The clinical trials of cefuroxim in the treatment of patients with various postnatal diseases and postoperative complications caused by Staph. aureus, E. coli, Klebsiella or Proteus showed its high efficacy. No adverse reactions of the drug were observed in any of 24 patients. The drug was rapidly absorbed on its intramuscular administration. Its therapeutic concentrations in the blood, milk and urine persisted for 8 hours after a single administration. Cefuroxim may be recommended for the treatment of patients with moderately severe infections. The single dose is 750 mg administered every 8 hours. However, in patients with severe postoperative complications cefuroxim should be used in combination with antibiotics preventing directed selection of the microorganisms resistant to cefuroxim (nonsporulating anaerobic bacteria, Ps. aeruginosa).
